Organic Active Ingredients TRIZ Cases

Myricetin derivatives from Parrotia persica accelerate wound healing while avoiding inflammatory responses linked to synthetic growth factors.

Novel lipid preparations form stable complexes with nucleic acids, resisting serum-induced aggregation and maintaining delivery capability.

Bi-heteroaryl compounds inhibit Vps34 to sensitize resistant cancer cells to metabolic stress and apoptosis.

Stable aqueous suspension of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-ketone particles prevents precipitation in high water content formulations.

A novel compound regulates epithelial-mesenchymal transition to prevent fibrosis.

A hydrophilic pyrazine derivative emits spectral energy under visible light to assess renal function through direct optical detection.

Specific double-stranded RNA sequences target JAK1 and JAK3 genes to minimize off-target effects while maximizing therapeutic efficacy.

Pyridinone dicarboxamide compounds selectively inhibit bromodomain 2 of BET proteins to treat autoimmune and inflammatory conditions.

Delivering a truncated Dgkk gene via AAV9 vectors overcomes FMRP-mediated repression to restore protein function and improve behavioral phenotypes.

Segmenting ezetimibe and rosuvastatin into separate layers prevents pharmaceutical interactions that decrease dissolution, ensuring stable release profiles.

Inverted core-shell nanoassemblies prevent electron transfer quenching while maintaining colloidal stability for precise bioimaging.

Novel triazolopyridine compounds modulate gamma-secretase activity to alter amyloid beta cleavage patterns.

Screening method identifies beta-adrenergic ligands that increase GLUT4 translocation without elevating cAMP production.

Formula I quinolinone compounds inhibit Syk kinase activity to reduce tumor cell survival.

Benzo-fused heterocycle sulfamide derivatives reduce body weight and delay gastric emptying to treat obesity in patients with BMI 25-30.

Novel 3-pyridyl carboxamide compounds inhibit spleen tyrosine kinase activity to treat inflammatory and autoimmune diseases.

Co-expressing porcine interferon-alpha and gamma in one adenovirus vector halves the required titer, boosting foot-and-mouth disease inhibition.

Allosteric modulators target the M4 receptor to improve therapeutic efficacy while avoiding peripheral cholinergic side effects and hepatotoxicity.

Amino acid excipients stabilize solid caspofungin acetate formulations, eliminating cold chain logistics requirements.

Formula I compounds inhibit peptidylarginine deiminase 4 activity, mitigating pathological citrullination in rheumatoid arthritis and lupus.

Morphinan derivatives target pancreatic NMDA receptors to stimulate insulin release only at elevated glucose concentrations.

A lipid nanoparticle with a pH-sensitive cationic lipid enhances nucleic acid introduction into target cells.

Compounds targeting GCN2 kinase improve treatment effectiveness while reducing adverse side effects in cancer therapy.

Exogenous fucosylated HMOs compensate for FUT2 genetic mutations to increase bifidobacteria abundance and restore gut barrier function.

Drug-eluting sinus scaffolds stabilize openings and prevent tissue adhesion, reducing inflammation without invasive surgery.

Indazole derivatives stimulate endogenous insulin release in response to glucose, reducing hypoglycemia risk while preserving beta-cell function.

Combining an FGFR inhibitor with an anti-PD1 antibody targets urothelial carcinoma through synergistic mechanism.

Antisense oligonucleotides induce exon skipping in VEGF-A pre-mRNA to reduce tumor growth while avoiding antibody side effects.

Papaverine derivatives block mitochondrial complex I to reduce tumor oxygen consumption, overcoming hypoxia-induced radiation resistance in cancer treatment.

KRAS mutation status predicts patient sensitivity to Cdc7 kinase inhibitors, reducing ineffective treatments and resource waste.

A stable injectable composition uses specific bile acid ratios to selectively induce apoptosis in adipocytes.

Optimized Lonicera Japonica flower water extract with secoxyloganin treats Helicobacter pylori infection while avoiding antibiotic resistance and side effects.

Modified CAPH peptides penetrate mammalian cells via electrostatic interactions, destroying intracellular microbes while minimizing host cytotoxicity.

Macrocyclic compounds inhibit the hepatitis C virus NS3 protease to overcome limited clinical benefits of current therapies.

aPKC inhibitors target atypical protein kinase C to reduce dietary-induced obesity and improve glucose metabolism without harsh side effects.

Segmented microneedles penetrate dense scalp barriers to deliver aptamers via hybridization kinetics, eliminating invasive injection procedures.

Tradipitant targets substance P via NK-1 antagonism to prevent cytokine storms and acute respiratory distress syndrome.

Incorporating antioxidant additives into furandicarboxylate monomers prevents oxidative yellowing, maintaining polymer clarity for packaging applications.

Cyclodextrins solubilize hydrophobic imiquimod in aqueous cores, resolving low pH solubility barriers for injectable co-formulation.

Guanidine derivatives activate PPARδ transcriptional activity by forming hydrogen bonds with specific amino acid residues in the ligand-binding pocket.

IDO1 inhibitors suppress pathological neovascularization in retinopathy while preserving normal vascular development through local immunometabolic modulation.

Specific WEE1 kinase inhibitors disrupt the G2 checkpoint to induce mitotic catastrophe, sparing normal cells with intact G1 checkpoints.

GGTI-2417 upregulates p27Kip1 to overcome Rho-mediated downregulation and induce apoptosis in breast tumors.

Generating transplantable beta cells via FoxO1 and Wnt inhibitors to overcome the critical shortage of pancreatic islet donors.

Selected Bifidobacterium longum strain expresses exopolysaccharides with 6-deoxy tallose to resolve gastrointestinal survival and bile tolerance contradictions.